Zheng Shengqi, Hua Tianchi, Yin Guicao, Zhang Wei, Wang Xiaoxiang, Qi Lezhong, Jing Xiayong, Fan Qibing, Yu Xiaoping, Li Yifan
Department of Urology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
Department of Health Promotion Center, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
Front Endocrinol (Lausanne). 2025 Jan 21;15:1406065. doi: 10.3389/fendo.2024.1406065. eCollection 2024.
Metabolic dysfunction-associated fatty liver disease (MAFLD) and nephrolithiasis are two common metabolic diseases, but their relationship has not yet been thoroughly studied. Therefore, this study aimed to explore the association between MAFLD and nephrolithiasis and to assess the effect of MAFLD on the risk of nephrolithiasis.
This cross-sectional study included 96,767 adults from China. All participants underwent medical examinations, including physical examinations, medical history tests, and laboratory tests. Based on ultrasound examination, participants were divided into MAFLD and non-MAFLD groups, and the severity of liver steatosis was determined based on ultrasound images. The relationship between MAFLD and nephrolithiasis was analyzed using a multivariate logistic regression model and subgroup analysis was performed.
The proportion of participants with MAFLD was significantly higher in the nephrolithiasis group compared to the non-nephrolithiasis group (47.70% vs. 30.45%, < 0.001). Multivariate logistic regression analysis showed a significant positive association between MAFLD and nephrolithiasis (adjusted =1.38, 95% : 1.29 to 1.47). Subgroup analyses indicated that, even after accounting for various factors such as age, diabetes, hypertension, obesity, lipid profiles, and renal function, the positive association between MAFLD and an increased risk of nephrolithiasis remained consistent. Further subgroup analysis revealed that in male patients with MAFLD, the risk of nephrolithiasis increased progressively with increasing severity of liver steatosis. The adjusted multivariable odds ratios were 1.43 (95% : 1.33 to 1.53) for mild, 1.48 (95% : 1.32 to 1.67) for moderate, and 1.94 (95% : 1.47 to 2.58) for severe hepatic steatosis.
This study found a significant positive association between MAFLD and nephrolithiasis. The risk of nephrolithiasis in males with MAFLD increased substantially with increasing severity of liver steatosis. Therefore, it is essential to strengthen prevention and screening for nephrolithiasis in individuals with MAFLD. More research is needed to elucidate the physiological and pathological mechanisms between MAFLD and nephrolithiasis.
代谢功能障碍相关脂肪性肝病(MAFLD)和肾结石是两种常见的代谢性疾病,但它们之间的关系尚未得到充分研究。因此,本研究旨在探讨MAFLD与肾结石之间的关联,并评估MAFLD对肾结石风险的影响。
这项横断面研究纳入了96767名中国成年人。所有参与者均接受了医学检查,包括体格检查、病史询问和实验室检查。根据超声检查结果,将参与者分为MAFLD组和非MAFLD组,并根据超声图像确定肝脂肪变性的严重程度。采用多因素logistic回归模型分析MAFLD与肾结石之间的关系,并进行亚组分析。
与非肾结石组相比,肾结石组中MAFLD参与者的比例显著更高(47.70%对30.45%,<0.001)。多因素logistic回归分析显示MAFLD与肾结石之间存在显著正相关(校正后=1.38,95%可信区间:1.29至1.47)。亚组分析表明,即使在考虑了年龄、糖尿病、高血压、肥胖、血脂谱和肾功能等各种因素后,MAFLD与肾结石风险增加之间的正相关仍然一致。进一步的亚组分析显示,在患有MAFLD的男性患者中,肾结石风险随着肝脂肪变性严重程度的增加而逐渐增加。轻度肝脂肪变性的校正多变量比值比为1.43(95%可信区间:1.33至1.53),中度为1.48(95%可信区间:1.32至1.67),重度为1.94(95%可信区间:1.47至2.58)。
本研究发现MAFLD与肾结石之间存在显著正相关。患有MAFLD的男性患肾结石的风险随着肝脂肪变性严重程度的增加而大幅增加。因此,加强对MAFLD患者肾结石的预防和筛查至关重要。需要更多的研究来阐明MAFLD与肾结石之间的生理和病理机制。